2025 Q4 -tulosraportti
14 päivää sitten
‧39 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 574 | NON | NON | ||
| 26 | NON | NON | ||
| 65 | NON | NON | ||
| 99 | SSWM | NON | ||
| 2 000 | AVA | NON |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
·1 päivä sittenWhen one looks at available trades, there are constantly 4000 shares cycling between the highest price and a bit cheaper, respectively, first on the sell side, then conversely on the buy side. Is it a bot that just constantly day trades? There is currently approx. 4% difference between sell and buy. So one could well imagine that a bot optimizes on buy/sell? Is that perhaps the case?
·1 päivä sittenSee or rewatch CSO Andreas Kjær's presentation in connection with the .TD Cowen conference from last week: Andreas Kjær reviews the case, preliminary data, competitive situation/market potential, patent protection, timeline towards 2029 etc.. The presentation gives a very good all-round picture of where the company is (wishes to be) headed. Together with CSO Andreas Kjær and CEO Ulrich Krasilnikoff, Jesper M. Lange, Senior Executive Advisor from Gorrisen Federspiel, also participated. Jesper M. Lange describes himself as follows on his LinkedIn profile: "I bring a unique combination of business and legal acumen, with a proven track record in both executive advisory and CEO leadership roles. At Gorrissen Federspiel my role is to assist biotech and pharma companies with (non-legal) strategy and operational execution in the preparation of significant inflection points and transactions (VC-funding, M&A, IPO, licensing, strategic partnerships, Growth funding etc.)." https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/ibNkhKEwKtK7iUrQ6v5xFB?fbclid=IwY2xjawQc3QRleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeIfTCMrDXDhA8I7gurKclQZWaXIPo1qTI_clnUdUoMU8q2FtMzlj1sghi6cM_aem_nZnpxwzD3WHTXwOXAclVEg
·2 päivää sitten · Muokattuhttps://biostock.se/en/2026/03/curasight-minskar-skulden-genom-konvertering-fran-fenja-capital/ After the presentation at the conference last week, some doubt arose regarding Topline data that was reported for Q3 Ulrich continues to say in this article "data readout before the summer" So we can still expect preliminary efficacy data in H1 and Topline in Q3 It will be really exciting. What the share price is until then doesn't interest me very much. It will be data that will form the basis for my decisions. Data is King!
·1 päivä sittenI have a naive belief that if it works on the first 10 - 12 people, then there are also good chances that it will work on a slightly larger scale. It's not like Alzheimer's or dementia, where it can be difficult to document that a preparation works. Here, as far as I can assess, it's more a case of “what you see is what you get”.- ·2 päivää sitten · MuokattuHopefully we can stay above 15kr, because it could otherwise look like some are trying to push the price further down to buy cheaper. They certainly won't get my shares at least :)
·2 päivää sittenThere is almost no trading in the stock. 52859 units today here 14:10. If you want to buy 7000 units right now, the price will end up over 16.·2 päivää sitten · MuokattuI agree it can change quickly, but the volume on the stock however looks very much like the other days we have had plenty of with around 0.8m to 1.4m. Trust the process as one says :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
14 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
- ·1 päivä sittenWhen one looks at available trades, there are constantly 4000 shares cycling between the highest price and a bit cheaper, respectively, first on the sell side, then conversely on the buy side. Is it a bot that just constantly day trades? There is currently approx. 4% difference between sell and buy. So one could well imagine that a bot optimizes on buy/sell? Is that perhaps the case?
- ·1 päivä sittenSee or rewatch CSO Andreas Kjær's presentation in connection with the .TD Cowen conference from last week: Andreas Kjær reviews the case, preliminary data, competitive situation/market potential, patent protection, timeline towards 2029 etc.. The presentation gives a very good all-round picture of where the company is (wishes to be) headed. Together with CSO Andreas Kjær and CEO Ulrich Krasilnikoff, Jesper M. Lange, Senior Executive Advisor from Gorrisen Federspiel, also participated. Jesper M. Lange describes himself as follows on his LinkedIn profile: "I bring a unique combination of business and legal acumen, with a proven track record in both executive advisory and CEO leadership roles. At Gorrissen Federspiel my role is to assist biotech and pharma companies with (non-legal) strategy and operational execution in the preparation of significant inflection points and transactions (VC-funding, M&A, IPO, licensing, strategic partnerships, Growth funding etc.)." https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/ibNkhKEwKtK7iUrQ6v5xFB?fbclid=IwY2xjawQc3QRleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeIfTCMrDXDhA8I7gurKclQZWaXIPo1qTI_clnUdUoMU8q2FtMzlj1sghi6cM_aem_nZnpxwzD3WHTXwOXAclVEg
- ·2 päivää sitten · Muokattuhttps://biostock.se/en/2026/03/curasight-minskar-skulden-genom-konvertering-fran-fenja-capital/ After the presentation at the conference last week, some doubt arose regarding Topline data that was reported for Q3 Ulrich continues to say in this article "data readout before the summer" So we can still expect preliminary efficacy data in H1 and Topline in Q3 It will be really exciting. What the share price is until then doesn't interest me very much. It will be data that will form the basis for my decisions. Data is King!·1 päivä sittenI have a naive belief that if it works on the first 10 - 12 people, then there are also good chances that it will work on a slightly larger scale. It's not like Alzheimer's or dementia, where it can be difficult to document that a preparation works. Here, as far as I can assess, it's more a case of “what you see is what you get”.
- ·2 päivää sitten · MuokattuHopefully we can stay above 15kr, because it could otherwise look like some are trying to push the price further down to buy cheaper. They certainly won't get my shares at least :)·2 päivää sittenThere is almost no trading in the stock. 52859 units today here 14:10. If you want to buy 7000 units right now, the price will end up over 16.·2 päivää sitten · MuokattuI agree it can change quickly, but the volume on the stock however looks very much like the other days we have had plenty of with around 0.8m to 1.4m. Trust the process as one says :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 574 | NON | NON | ||
| 26 | NON | NON | ||
| 65 | NON | NON | ||
| 99 | SSWM | NON | ||
| 2 000 | AVA | NON |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
2025 Q4 -tulosraportti
14 päivää sitten
‧39 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 23.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 1.12.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 25.4.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenChanges are happening in the board of directors: • Two are stepping down: • Lars Trolle • Charlotte Vedel • Two new ones are proposed: • Marcel Reichen • Colin Hayward Marcel Reichen • International biotech and pharma profile • Has worked in biotech investment and company development • Often involved in strategy and capital raising in life-science companies. Typical type one brings in if one wants to strengthen financing or partnerships. ⸻ Colin Hayward • Many years of experience in pharma and biotech management • Has worked with development and commercialization of medicine. • Experience with international biotech companies.
- ·1 päivä sittenWhen one looks at available trades, there are constantly 4000 shares cycling between the highest price and a bit cheaper, respectively, first on the sell side, then conversely on the buy side. Is it a bot that just constantly day trades? There is currently approx. 4% difference between sell and buy. So one could well imagine that a bot optimizes on buy/sell? Is that perhaps the case?
- ·1 päivä sittenSee or rewatch CSO Andreas Kjær's presentation in connection with the .TD Cowen conference from last week: Andreas Kjær reviews the case, preliminary data, competitive situation/market potential, patent protection, timeline towards 2029 etc.. The presentation gives a very good all-round picture of where the company is (wishes to be) headed. Together with CSO Andreas Kjær and CEO Ulrich Krasilnikoff, Jesper M. Lange, Senior Executive Advisor from Gorrisen Federspiel, also participated. Jesper M. Lange describes himself as follows on his LinkedIn profile: "I bring a unique combination of business and legal acumen, with a proven track record in both executive advisory and CEO leadership roles. At Gorrissen Federspiel my role is to assist biotech and pharma companies with (non-legal) strategy and operational execution in the preparation of significant inflection points and transactions (VC-funding, M&A, IPO, licensing, strategic partnerships, Growth funding etc.)." https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/ibNkhKEwKtK7iUrQ6v5xFB?fbclid=IwY2xjawQc3QRleHRuA2FlbQIxMQBzcnRjBmFwcF9pZBAyMjIwMzkxNzg4MjAwODkyAAEeIfTCMrDXDhA8I7gurKclQZWaXIPo1qTI_clnUdUoMU8q2FtMzlj1sghi6cM_aem_nZnpxwzD3WHTXwOXAclVEg
- ·2 päivää sitten · Muokattuhttps://biostock.se/en/2026/03/curasight-minskar-skulden-genom-konvertering-fran-fenja-capital/ After the presentation at the conference last week, some doubt arose regarding Topline data that was reported for Q3 Ulrich continues to say in this article "data readout before the summer" So we can still expect preliminary efficacy data in H1 and Topline in Q3 It will be really exciting. What the share price is until then doesn't interest me very much. It will be data that will form the basis for my decisions. Data is King!·1 päivä sittenI have a naive belief that if it works on the first 10 - 12 people, then there are also good chances that it will work on a slightly larger scale. It's not like Alzheimer's or dementia, where it can be difficult to document that a preparation works. Here, as far as I can assess, it's more a case of “what you see is what you get”.
- ·2 päivää sitten · MuokattuHopefully we can stay above 15kr, because it could otherwise look like some are trying to push the price further down to buy cheaper. They certainly won't get my shares at least :)·2 päivää sittenThere is almost no trading in the stock. 52859 units today here 14:10. If you want to buy 7000 units right now, the price will end up over 16.·2 päivää sitten · MuokattuI agree it can change quickly, but the volume on the stock however looks very much like the other days we have had plenty of with around 0.8m to 1.4m. Trust the process as one says :-)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 574 | NON | NON | ||
| 26 | NON | NON | ||
| 65 | NON | NON | ||
| 99 | SSWM | NON | ||
| 2 000 | AVA | NON |
Välittäjätilasto
Dataa ei löytynyt